36 terminated. 36 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Terminated 36 |
| Phase 2 | 13 | Terminated 13 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS) Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air - Acute Respiratory Distress Syndrome, Sepsis | Phase 1 | Terminated | Brigham and Women's Hospital | 5 | 2023-12-06 | 2026-05-26 |
| Beta-glucan and Fatigue in HSCT Survivors Beta-glucan, Placebo - Autologous Haemopoietic Stem Cell Transplant | Phase 1 / Phase 2 | Terminated | University of Florida | 3 | 2023-02-10 | 2023-10-24 |
| [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine 11(R)-rolipram - Depression | Phase 1 | Terminated | National Institute of Mental Health (NIMH) | 1 | 2023-02-08 | 2024-03-05 |
| [18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects 18F-SF12051 - Healthy | Phase 1 | Terminated | National Institute of Mental Health (NIMH) | 10 | 2023-02-02 | 2024-07-09 |
| Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) MHS552, Placebo - Lupus Erythematosus, Systemic | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2022-03-15 | 2024-10-09 |
| HAT for the Treatment of Sepsis Associated With NASTI HAT, Placebo - Necrotizing Soft Tissue Infection, Sepsis | Phase 1 / Phase 2 | Terminated | Ascension Health | 10 | 2021-09-10 | 2024-07-24 |
| Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients GEM00220 - Septic Shock | Phase 1 | Terminated | Northern Therapeutics | 11 | 2021-08-11 | 2024-04-16 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
| Tofacitinib in Depression (TIDE) Tofacitinib 5 MG [Xeljanz], Placebo - Depression, Inflammation | Phase 1 / Phase 2 | Terminated | University of Oxford | 2 | 2020-02-10 | 2022-08-09 |
| PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan - Dementia | Phase 1 | Terminated | National Institute of Mental Health (NIMH) | 13 | 2019-07-03 | 2024-05-01 |
| Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD Omega 3 fatty acids, Placebo - Heart Failure, Gastrointestinal Bleeding | Phase 1 / Phase 2 | Terminated | University of Chicago | 35 | 2019-01-23 | 2021-07-13 |
| Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Stress-dose Hydrocortisone plus Vitamin C, isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo - Septic Shock | Phase 1 / Phase 2 | Terminated | University of Athens | 26 | 2018-09-06 | 2024-12-19 |
| Effects of Probiotic on Inflammation and Microbiota in Patients With NASH Probiotic Formulation VSL#3 - Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018 | Phase 1 / Phase 2 | Terminated | Northwell Health | 6 | 2018-05-15 | 2020-01-07 |
| Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis ATA188, Placebo - Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Atara Biotherapeutics | 134 | 2017-10-19 | 2024-02-23 |
| Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock 25% Albumin, Placebo - Shock, Septic | Phase 1 | Terminated | Alexander Flannery, 859-323-4011 | 11 | 2016-03-01 | 2019-04-04 |
| Oxytocin Aging Study Intranasal Oxytocin spray, Intranasal Placebo spray - Inflammation | Phase 1 | Terminated | University of Florida | 153 | 2016-02-01 | 2020-06-19 |
| Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis BMS-936559, Placebo - Severe Sepsis, Septic Shock | Phase 1 | Terminated | Bristol-Myers Squibb | 35 | 2015-12-02 | 2017-09-15 |
| Evaluating Muscle Weakness Improvement With Lorcaserin in ICU Lorcaserin, Placebo - Muscle Weakness, Sepsis | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 5 | 2015-12-01 | 2020-01-13 |
| Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection Anakinra - HIV Infections, Neurologic Disorders | Phase 1 | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | 1 | 2015-08-17 | 2019-11-29 |
| Resveratrol and Cardiovascular Health in the Elderly Resveratrol, Placebo - Vascular Resistance, Hypertension | Phase 1 / Phase 2 | Terminated | National Institute on Aging (NIA) | 73 | 2015-07-14 | 2022-12-23 |
Showing 20 of 36. Sign in to see all of them.
Sepsis (10) · Shock, Septic (5) · Depression (3) · Acute Lung Injury (2) · Autoimmune Diseases (2) · Lupus Erythematosus, Systemic (2) · Neuroinflammatory Diseases (2) · Psoriasis (2) · Respiratory Distress Syndrome (2) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Bacterial Infections (1) · COVID-19 (1) · Carotid Artery Diseases (1)
Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Infections (15) · Systemic Inflammatory Response Syndrome (13) · Nervous System Diseases (6) · Shock (6) · Cardiovascular Diseases (4) · Immune System Diseases (4) · Respiratory Tract Diseases (4) · Signs and Symptoms (4) · Skin and Connective Tissue Diseases (4) · Behavior (3) · Behavioral Symptoms (3) · Digestive System Diseases (3)
Ascorbic Acid (2) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · AMG 557 (1) · Adenosine (1) · Albumins (1) · Analgesics, Opioid (1) · Anti-Inflammatory Agents, Non-Steroidal (1) · BMS-936559 (1) · Blood Specimen Collection (1) · Carnitine (1) · Celecoxib (1) · Fatty Acids, Omega-3 (1) · Fentanyl (1) · Hydrocortisone (1) · Immunoglobulins, Intravenous (1)
National Institute of Mental Health (NIMH) (3) · University of Florida (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novo Nordisk A/S (2) · Vanderbilt University (2) · Alexander Flannery, 859-323-4011 (1) · Amgen (1) · Ascension Health (1) · Atara Biotherapeutics (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Federal University of São Paulo (1) · Indiana University (1) · Johns Hopkins University (1) · Medical University of Vienna (1)
United States (27) · Canada (2) · Australia (1) · Austria (1) · Brazil (1) · Germany (1) · Greece (1) · Hungary (1) · Poland (1) · Russia (1) · Serbia (1) · Switzerland (1) · United Kingdom (1)
Robert B Innis, M.D. (3) · Ajoy C Karikkineth, M.D. (1) · Alan E Jones, MD (1) · Alexander H. Flannery, Pharm.D. (1) · Anastasia Kotanidou, MD, PhD (1) · Ann Nguyen, MD (1) · Avindra Nath, M.D. (1) · Christian Madl, MD (1) · Dale M Needham, MD, PhD (1) · Daniel Fowler, M.D. (1) · Daniel Martin, Ph.D., PT (1) · Fernando Paganelli, MD (1)
PMID 19234342, PMID 24088271, PMID 25749867, PMID 25901477, PMID 26252485, PMID 26514420, PMID 26825368, PMID 28523582, PMID 30590569, PMID 30747773, PMID 32140727, PMID 32325487, PMID 38104476, PMID 38241758, PMID 39654356
P30AG028740 (1), R61HL153011 (1), UL1TR001079 (1)